|Articles|April 16, 2015

Spring Rorschach Test

Keeping the season in mind, what is your first impression of this image?

Hermann Rorschach was a Swiss Freudian psychiatrist and psychoanalyst. Dr Rorschach is remembered for having developed the Rorschach inkblot test.

Related contentCelebrating Rorschach's BirthdayThe Human Heart of PsychiatryLove and Rorschach: A Valentine Quiz

This article was originally posted on May 13, 2015, and has since been updated.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Podcast: What Public Health Can Teach Us About Culturally Affirming Care

ByFrank A. Clark, MD,Shambrekia Wise

September 2nd 2026

John J. Miller, MD, on the Biopsychosocial Model in Psychiatry

ByJohn J. Miller, MD

August 28th 2026

Cultural Competency and Community Engagement in Psychiatric Practice

ByNaomi Dambreville, PhD

August 21st 2026

Collaborative Psychiatric-Dermatologic Care Improves Outcomes for Complex Patients

ByJames A. Bourgeois, OD, MD,Xiaofeng Yan, MD, PhD

August 21st 2026

How Does the Skin-Brain Connection Drive Skin-Picking Disorder?

ByJames A. Bourgeois, OD, MD,Xiaofeng Yan, MD, PhD

August 20th 2026

Latest CME

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Spring Rorschach Test

Related Content

Podcast: What Public Health Can Teach Us About Culturally Affirming Care

John J. Miller, MD, on the Biopsychosocial Model in Psychiatry

Cultural Competency and Community Engagement in Psychiatric Practice

Collaborative Psychiatric-Dermatologic Care Improves Outcomes for Complex Patients

How Does the Skin-Brain Connection Drive Skin-Picking Disorder?

Latest CME

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Trending on Psychiatric Times

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know